Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Shapira

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
The Journal of Endocrinology|February 1, 1997
Large-scale preparation and characterization of recombinant ovine placental lactogenE Sakal, C Bignon, J Grosclaude, et al.
Harefuah|July 26, 2000
[Living-related liver transplantation--first experiences at Rabin Medical Center]N Bar-Nathan, Z Shapira, E Shaharabani, et al.
Protein Science : a Publication of the Protein Society|March 22, 2003
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibodyBarbara E Power, Larissa Doughty, Deborah R Shapira, et al.
The Journal of Cell Biology|August 22, 2001
Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phoxW A Edens, L Sharling, G Cheng, et al.
Cancer Immunology, Immunotherapy : CII|August 14, 2001
Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vectorB E Power, J M Caine, J E Burns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyU A Matulonis, R T Penson, S M Domchek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
Oncogene|October 1, 2013
FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesisK Levanon, S Sapoznik, K Bahar-Shany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2022
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)A Zer, O Icht, L Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Endocrinology|February 1, 1997
Large-scale preparation and characterization of recombinant ovine placental lactogenE Sakal, C Bignon, J Grosclaude, et al.
Harefuah|July 26, 2000
[Living-related liver transplantation--first experiences at Rabin Medical Center]N Bar-Nathan, Z Shapira, E Shaharabani, et al.
Protein Science : a Publication of the Protein Society|March 22, 2003
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibodyBarbara E Power, Larissa Doughty, Deborah R Shapira, et al.
The Journal of Cell Biology|August 22, 2001
Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phoxW A Edens, L Sharling, G Cheng, et al.
Cancer Immunology, Immunotherapy : CII|August 14, 2001
Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vectorB E Power, J M Caine, J E Burns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyU A Matulonis, R T Penson, S M Domchek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
Oncogene|October 1, 2013
FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesisK Levanon, S Sapoznik, K Bahar-Shany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2022
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)A Zer, O Icht, L Yosef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 10